medicare coverage for glp-1 drugs are covered by Big News Part D Patients! 🎉 Starting July Medicare obesity drug GLP-1 coverage

FOXO4-DRI may reduce age-related inflammation Senescent cells often release pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP)

In confirmation of this finding, Khani et al

What This Means For Patients Better adherence = better outcomes Reduced cardiovascular disease risk More people actually taking their medication Fewer heart attacks and strokes prevented The most effective drug is the one patients actually take

This category primarily consists of ASOs, siRNAs, miRNAs, small activating RNAs (saRNAs), and the CRISPR/Cas system, which enables precise gene editing of genomic DNA